Sponsored by VisionaryHealthConcepts  

(creators of www.freehivinfo.com)  

 

 

 

Conference Update:

 The American Association for the Study of Liver Diseases (AASLD)

November 11-15, 2005

San Francisco, California

 

 HBV

 

AASLD: Adefovir Add-on Therapy after Emergence of Lamivudine Resistance Is Effective and Unlikely to Result in Resistance to Adefovir in HIV-HBV Coinfected Patients  

 

AASLD: A Cost-Effectiveness Analysis of Treatment Alternatives for Hepatitis B Cirrhosis  

 AASLD: Entecavir Two-Year Resistance Update

 

AASLD: Treatment with Tenofovir Results in a Rapid Decrease of HBV-DNA Viral Load in Patients with Resistance or Sub-optimal Response to Adefovir  

AASLD: Tenofovir Appears Highly Effective as Salvage Therapy for HBV Patients with Suboptimal Response to Adefovir

 

AASLD: HEPATITIS B: SCIENCE & TREATMENT 2005

Interleukin-12 Does Not Halt HBV Replication in HBeAg Positive Patients and Does Not Inhibit

 

HCV

AASLD: Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study 12/14/04)

 

AASLD: Safety of Double Dose Pegasys (REPEAT Study) (12/12/05)
 

AASLD: 24 Week Pegasys+RBV Treatment SVR in Genotype 1 Predicted by Wk 4 Response (12/07/05)
 

AASLD: Randomized Trial of Valopicitabine (NM 283), Alone or with Peginterferon, vs Retreatment with Peginterferon Plus Ribavirin in Nonresponders to Peginterferon Alfa -

AASLD: No Effect of Pegylated Interferon Alfa-2b (PegIntron) on the Pharmacokinetics of Valopicitabine (NM 283) in Chronic HCV Patients

 

AASLD: INDEPENDENT VALIDATION AND COMPARISON WITH FIBROSCAN, FIBROTEST AND LIVER BIOPSY OF CLINICAL GLYCOMICS FOR THE NON INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV  

 

AASLD: Hispanics Developed Cirrhosis More Quickly Due to the presence of Fatty Liver & Diabetes

 

AASLD: SCH 503034 HCV Protease Inhibitor Monotherapy in HCV Genotype 1 IFN Nonresponders

 

AASLD: REPEAT Study: Non-responders to ≥12 weeks' treatment with standard-dose pegylated interferon alfa-2b (PegIntron) plus ribavirin received standard dose of Pegasys + ribavrin or double dose Pegasys + ribavirin

 

AASLD: VX-950 Hep C Protease Inhibitor

 

AASLD: Is Shorter Treatment with Peginterferon Alfa-2a (Pegasys) Plus Ribavirin Possible in HCV Genotype 1 'Super Responders'?

 

AASLD:  Does Weight-based Ribavirin Dosing Increase Sustained Viral Response in Patients with Chronic Hepatitis C? Final Results of the WIN-R Study

 

Home | CME Zone | Hepatitis Education | Join Mailing List | About Us | News Archive | Links | Contact Us